Clinical Trial

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the safety, tolerability, and efficacy of BBM-D101 to treat participants with Duchenne Muscular Dystrophy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-01; most recent amendment 2025-11-28.
Status change: Not Yet Recruiting → Recruiting 2025-08-19
Trial Details
NCT Number NCT07058662
Lead Sponsor Belief BioMed (Beijing) Co., Ltd
Collaborators: Shanghai Mianyi Biopharmaceutical Co., Ltd., Shanghai Xinzhi BioMed Co., Ltd., Belief BioMed Limited
Conditions DMD
Enrollment 9 participants
Start Date 2025-07-31
Primary Completion 2027-06-30 (estimated)
Study Completion 2031-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-04